US Market Report for Continuous Glucose Monitoring 2017 – MedCore

US Market Report for Continuous Glucose Monitoring 2017 – MedCore

0

  • Year: 2017
  • Scope: 2013-2023
  • Region: United States
  • Published Date: 11/1/16
  • Pages: 74
  • Type: MedCore

Continuous glucose monitoring (CGM) allows for a more accurate reading of how blood glucose levels fluctuate throughout the day by measuring interstitial glucose levels on a continuous basis and estimating blood glucose levels based on these readings. A CGM system is typically made up of three components: a glucose sensor, transmitter and receiver. The sensor is inserted under the skin into the interstitial fluid and held with an adhesive. Sensors are typically sold in groups of four and are labeled for six to seven days of use, depending on the manufacturer. A transmitter takes the glucose reading from the sensor and wirelessly sends it to a small, hand-held receiver. If glucose levels are too low or high, the receiver warns the patient. Some manufacturers have even built-in a threshold audible alarm as a fixed safety feature when the patient approaches levels below 55 mg/dL, at which point the patient is still interactive but severely hypoglycemic.

The U.S. continuous glucose monitoring (CGM) market can be segmented by setting, yielding two segments: professional CGM and personal CGM. In 2016, the largest segment in the total CGM market was the personal CGM segment. Growth is expected to continue over the forecast period and will be driven by favorable reimbursement, technological innovation and increased uptake of personal CGM among type 1 diabetics and insulin-dependent type 2 diabetics. Professional CGM is typically used in retrospective sessions initiated by physicians, during which a patient wears a CGM sensor for several days to a week, but is ‘blinded’ to the real-time CGM data and must adhere to frequent self-monitoring of blood glucose (SMBG) using traditional blood glucose meters. Additionally, the patient must maintain a record of their daily dietary intake and activity during the time that the sensor is worn. At the end of the session, the patient returns to their physician to remove the sensor and retrospectively analyze the glucose data that was collected. The ‘blinded’ aspect of professional CGM allows physicians to more easily assess their patient’s behavior because their actions are not influenced by ‘real-time’ glucose data, as is the case with personal CGM products.



The "US Market Report Suite for Diabetes Monitoring, Treatment and Drug Delivery 2017 - MedSuite" includes analysis on the following companies currently active in this market:
Sanofi
Novo Nordisk
Eli Lilly
Medtronic
Johnson & Johnson
Becton Dickinson
Abbott
Roche
DexCom
Ascensia
Insulet
Trividia Health
Tandem
Nova Biomedical
Valeritas
*Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.




Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology

Thank you!

CLOSE
Report Type Info

Single License: A single license is for use by a single individual only. Usage rights may not be transferred, sold or distributed by any means.

Site License: A site license allows sharing of the reports between various users within the purchasing company’s designated business address within this agreement.

Corporate License: A corporate license is for the use of one corporation. A corporation is defined as any business entity incorporated under a single name. Separate corporations operating under the same parent company are not included in this license.

Executive Summary: An in-depth summary of the reports associated with the related MedSuite product.

CLOSE

Login

Sign Up

Already have an account? Sign in

×